Recently, one new highly specific and well-tolerated HIF-2α inhibitor, belzutifan, became FDA-approved for the treatment of nonmetastatic renal cell carcinomas and pancreatic neuroendocrine tumors [77]. This evidence concerns the gene EPAS1 and pancreatic neuroendocrine tumor.